Skip to main content
. Author manuscript; available in PMC: 2013 May 9.
Published in final edited form as: Leukemia. 2008 Jan 17;22(4):850–855. doi: 10.1038/sj.leu.2405091

Figure 3.

Figure 3

Overall survival of patients treated on TT and non-TT protocols from the time of relapse according to the presence or absence of cytogenetic abnormalities (CA) at baseline or relapse. Superior post-transplant survival was observed in patients lacking CA at both time-points, followed by patients with CA at baseline only, whereas those with CA pre-transplant fared poorly regardless of baseline CA status.